<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210217050394N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-03-08</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of evening primrose oil capsules on postpartum pain in multiparous women</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of evening primrose oil capsules on postpartum pain in multiparous women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-03-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54394</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Sampling in the midwifery clinic of Umm Al-Banin hospital will be done in an easy method, based on the inclusion and exclusion criteria, and using a simple randomization method, random allocation of samples will be done in different groups. Randomization method will be as follow: It is performed that the assignment sequence will be written before the beginning of the research. Given that 3 groups will be studied and each letter will be assigned to a group (A evening primrose capsule, B placebo and C control group with routine care). Randomization will be performed using Research Randomizer software, then inside the sealed and opaque packages, the type of intervention will be written based on the allocation sequence and packages will be numbered, Blinding description: Capsules will be encoded by the pharmacist. The capsules will be divided and numbered in opaque and sealed envelopes. Researchers and mothers will be unaware of group codes.</study_design>
      <phase>3</phase>
      <hc_freetext>Postpartum pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 1000 mg evening primrose oil capsule and made by Barij Essential Oil Company, available in the market, based on previous studies in the field of gynecology and obstetrics and with the advice of a pharmacist, its number and amount of use will be determined and considered for intervention at least 2 hours after delivery. The first dose will be given and the pain will be measured and recorded again one hour after taking the medicine. The intervention group will receive the capsule 4 times every 8 hours. At each intervention, pain intensity will be measured and recorded one hour before and one hour after. One hour after each intervention, if the pain will persist and the mothers request painkillers, a 500 mg acetaminophen tablet is given and recorded. Intervention 2: Placebo group: 1000 mg capsule containing paraffin, very similar to evening primrose capsule, at least 2 hours after delivery, the first dose will be given and one hour after taking the drug, the pain will be measured and recorded again. The group will receive the capsule 4 times every 8 hours. At each intervention, pain intensity will be measured and recorded one hour before and one hour after. One hour after each intervention, if the pain will persist and the mother requests painkillers, an acetaminophen 500 mg tablet is given and recorded. Intervention 3: Control group: In the control group, no intervention will be performed and if pain is expressed, they will receive routine analgesia (acetaminophen 500 mg).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Yes. There is a plan to publish.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Amin</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and MidwiferyMashhad Ibn Sina St.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>+98 51 3859 1511</telephone>
        <email>AminM982@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Samira Ebrahimzadeh Zagmi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mashhad, Ibn Sina St., School of Nursing and Midwifery</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>+98 51 3859 1511</telephone>
        <email>EbrahimzadehZS@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being Iranian
mother age between 18-35 years
singleton pregnancy with gestational age 37-42 weeks
normal delivery
live and seemingly healthy baby
baby weight between 4000-2500 grams
Normal delivery gravid 3-5
No use of narcotics and spinal and epidural anesthesia during labor
No cesarean section or previous uterine surgery
The second and third stages of normal delivery
Absence of medical disease and no grade 3 and 4 perineal and vaginal tears
Lack of sensitivity to medicinal plants and acetaminophen
Start breastfeeding until the first two hours after delivery and continue breastfeeding
Pain intensity (based on visual scale) 4 and more within 2 hours after delivery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>The mother's unwillingness to participation
Allergy to medicinal plants
Medical and midwifery problems
First pregnancy
Multiplication
Mother age should not be between 18-35</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z39</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Encounter for maternal postpartum care and examination</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 1000 mg evening primrose oil capsule and made by Barij Essential Oil Company, available in the market, based on previous studies in the field of gynecology and obstetrics and with the advice of a pharmacist, its number and amount of use will be determined and considered for intervention at least 2 hours after delivery. The first dose will be given and the pain will be measured and recorded again one hour after taking the medicine. The intervention group will receive the capsule 4 times every 8 hours. At each intervention, pain intensity will be measured and recorded one hour before and one hour after. One hour after each intervention, if the pain will persist and the mothers request painkillers, a 500 mg acetaminophen tablet is given and recorded.</i_keyword>
      <i_keyword>Placebo group: 1000 mg capsule containing paraffin, very similar to evening primrose capsule, at least 2 hours after delivery, the first dose will be given and one hour after taking the drug, the pain will be measured and recorded again. The group will receive the capsule 4 times every 8 hours. At each intervention, pain intensity will be measured and recorded one hour before and one hour after. One hour after each intervention, if the pain will persist and the mother requests painkillers, an acetaminophen 500 mg tablet is given and recorded.</i_keyword>
      <i_keyword>Control group: In the control group, no intervention will be performed and if pain is expressed, they will receive routine analgesia (acetaminophen 500 mg).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postpartum pain in multiparous women. Timepoint: Beginning and end of the study and during the first 24 hours of labor - every 8 hours - one hour before and one hour after the intervention. Method of measurement: McGill Pain Questionnaire and Visual Pain Scale (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-26</approval_date>
        <contact_name>Ethics Committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Khorasan Razavi, Mashhad, Daneshgah St., Ph.D. Intersection, Ibn Sina St., School of Nursing and Midwifery Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
